Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study

Hu, M; Taylor-Robinson, S.D.; Chaudhuri, K. Ray; Bell, Jimmy D.; Morris, Robin G.; Clough, C; Brooks, David J.; Turjanski, N

doi:10.1136/jnnp.67.1.20

Cited by 61 publications

(37 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the parietotemporal region, Hu et al [75] also found a relative decrease in the affected side. However, other reports found no difference comparing the affected side with the other [71][72][73], or between the left and right hand side of patients [69,76,77].…”

Section: Pd and Related Illnessesmentioning

confidence: 93%

A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson’s Disease

Firbank¹,

Harrison²,

O’Brien³

2002

Dement Geriatr Cogn Disord

123

View full text Add to dashboard Cite

We reviewed the literature of proton magnetic resonance spectroscopy (MRS) in dementia and Parkinson’s disease (PD) and quantitatively compared the reported values of the markers N-acetyl aspartate (NAA), choline, and myo-Inositol between control and disease groups. We analysed a total of 27 reports in dementia. Combining the quantitative data from these showed a relative decrease of 15% in NAA level in the temporal lobe tissue in patients with Alzheimer’s disease (AD) compared with controls. The rest of the brain showed a seemingly uniform 10% decrease in NAA levels in AD compared with controls. myo-Inositol was raised by about 15%, again uniformly throughout the brain, but there was no evidence for changed levels of choline. We found 15 reports of MRS in PD, which show a small decrease (5%) in the NAA level in the lentiform nucleus compared with controls. In progressive supranuclear palsy (PSP), there is a greater decrease in NAA levels in the frontal region and the lentiform nucleus. This may aid in the diagnosis of PSP. Further research is needed to determine spectroscopic changes in other dementias, to monitor how markers change with disease progression and to establish clinical utility.

show abstract

Section: Pd and Related Illnessesmentioning

confidence: 93%

A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson’s Disease

Firbank¹,

Harrison²,

O’Brien³

2002

Dement Geriatr Cogn Disord

123

View full text Add to dashboard Cite

show abstract

“…Many researchers disclosed a significant reduction of ratios NAA/Cr and NAA/Cho in the temporoparietal cortex [91], the substantia nigra, the basal ganglia [92], the striatum or the occipital lobe [93]. Griffith et al have demonstrated lower NAA/Cr ratios in the posterior cingulate gyrus of demented versus non demented subjects with PD [94].…”

Section: Neurodegenerative Diseases (Alzheimer/parkinson)mentioning

confidence: 99%

Proton Magnetic Resonance Spectroscopy of the Central Nervous System

Kousi¹,

Tsougos²,

Eftychia³

2013

Novel Frontiers of Advanced Neuroimaging

View full text Add to dashboard Cite

“…[3][4][5][6] In particular, a tremor-dominant type is usually distinguished from an akinetic-rigid type. [5][6][7] Neuroimaging techniques, including voxel-based morphometry, [8][9][10][11][12] proton MR spectroscopy, 13,14 positron-emission tomography (PET), [15][16][17][18] and single-photon emission tomography [19][20] demonstrate widespread changes in the cerebral hemispheres in patients in advanced clinical stages of PD. Recently, several studies pointed out the capability of the histogram analysis of the apparent diffusion coefficient computed from diffusion-weighted images and of the mean diffusivity and fractional anisotropy (FA) computed from diffusion tensor imaging (DTI) to reveal brain-tissue damage in neurodegenerative diseases with predominant involvement of the gray matter (GM), such as Alzheimer disease, 21 Huntington disease, 22 and progressive ataxias.…”

mentioning

confidence: 99%